Ticho Barry sold $153K of STOK

Ticho Barry (CHIEF MEDICAL OFFICER) sold 4,767 shares of Stoke Therapeutics, Inc. (STOK) at an average of $32.03 ($32.01–$32.47, $0.15M total) across 2 trades on 2026-08-18.

Original reporting
SEC EDGAR · Ticho Barry
Published Aug 19, 2026, 12:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 12:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STOK
Neutral
medium confidence
Mentioned
$STOK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STOKNeutralLow
01

Why it matters

This provides a new, dated datapoint on insider selling activity, but it does not include any new company guidance, trial results, regulatory actions, or deal terms that would directly reprice the business.

02

Market read

Traders may monitor insider activity as a sentiment input, but the disclosure alone is unlikely to drive a sustained move without additional fundamental catalysts.

03

What to watch

The filing lacks context on total holdings, prior sale cadence, and whether other insiders sold or bought around the same time, which can help distinguish routine liquidity from signaling.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18 after-hours; reflects sale executed 2026-08-18

Background

The article is an SEC Form 4 insider transaction disclosure for Stoke Therapeutics, Inc., reported by its Chief Medical Officer.

Company-level read

Ticker impact

$STOKNeutralMedium confidence
Context

Stoke Therapeutics Form 4 shows CMO Ticho Barry sold 4,767 shares in open-market transactions on 2026-08-18.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment and should fade unless paired with other company-specific catalysts.

Evidence & confidence

The filing is a primary-source insider transaction, but the article provides no new operational, clinical, or financial information, and the sale size is not described as extraordinary relative to typical insider activity.

Market effects

Minimal; insider selling in a single biotech name rarely resets sector expectations without accompanying clinical or regulatory news.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; absence of a stated 10b5-1 plan does not necessarily imply negative outlook.

Key entities

  • Stoke Therapeutics, Inc.

    Biopharma company subject of the Form 4 insider transaction disclosure.

  • Ticho Barry

    Chief Medical Officer who reported the open-market sale of STOK shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NOCMed

ULA’s Latest Launch Failure Spells Trouble for Space Force

United Launch Alliance's (ULA) Vulcan Centaur rocket failed during a Nov. 15 launch, destroying 40 Amazon satellites and tightening Space Force launch capacity. The issue was attributed to inadequate fuel supply to the BE-4 engines, built by Blue Origin. ULA faces further investigation, while SpaceX's successful Starship test cements its dominance.

$STOKMed

Stoke Therapeutics Q3 Earnings Call Highlights

Stoke Therapeutics (STOK) discussed Q3 earnings, highlighting plans for zorevunersen's NDA submission in 2027. The FDA supports a multicomponent endpoint for cognition/behavior. Stoke estimates 38,000 Dravet syndrome patients in key markets. STK-002 for ADOA is in Phase I trials. Q3 net loss was $73.6M, with $358.8M cash. Stoke expects funding into early 2028.

$STOKMed

Stoke Q3 2026 slides: EMPEROR trial advances with zero dropouts

Stoke Therapeutics (STOK) reported Q3 2026 progress, highlighting zero dropouts in its EMPEROR Phase 3 trial for zorevunersen in Dravet syndrome. The company beat revenue estimates but reported a wider-than-expected loss. Stoke has $358.8M in cash, enough to fund operations into early 2028. The trial enrolled 162 patients, exceeding the target, with strong patient retention and statistical significance in endpoints. The FDA has accepted the study's multicomponent approach for regulatory filing.

$STOKMed

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (STOK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX 99.1 Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates –Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all co

$STOKMedAI 8/10

About 110 patients reached the seizure-measurement point in a Dravet drug trial

Stoke Therapeutics reported progress in its Phase 3 EMPEROR study for zorevunersen, an investigational drug for Dravet syndrome, with 110 patients reaching the Week 28 primary endpoint. The company plans to submit data to the FDA in the first half of 2027 and complete the NDA submission in the second half. Additionally, the Phase 1 OSPREY study for STK-002, targeting ADOA, is ongoing with initial data expected in H1 2027.